drugset
drugset / Trial / NCT03546816

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

NCT03546816 ↗

Phase 3 Completed 285 enrolled Vyne Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Timeline

Start
2018-05-02
Primary completion
2020-01-14
Completion
2020-02-14

Outcome

Missed primary endpoint

registry analysis (superiority test); Serlopitant 5 mg vs Placebo; p = 0.229 NCT03546816 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Serlopitant Small molecule 5 mg —

Indications

prurigo nodularis